by my will provide what relevant reiterating and call investment and from of level high doing Joe. I at development a are comments and Caladrius our we last our today. begin attractive Thanks programs increasingly why are opportunities description
cell the of to the are As world. therapy need heart despite being and/or diseases. may of States space death the there's overlooked aware, areas, many cancers majority most leading be treating on advances and of and Though clearly United the a the you continues focused disease for companies rare these gene in in in developed be of cause
reverse is that clinical that have the diseases cardiovascular cell focused are opposed developing from a of that of late-stage clinical large manage biopharmaceutical factors with differentiate we One other underway Caladrius as data. to database we human on programs and therapies companies
have economical justified. Our effective, durable, therapies be and tolerated, been to-date well to pharmacoeconomically shown
provide said, our patients working with therapy on of products let summary cell therapy chronic CDXX+ Most with requires than we rather single importantly, providing the platform. a me basis With one that curative administration for of a goal are the readministration. that
that prevention led facilitating oxygenated technology of injury blood by microvasculature by the limited improved technology, to by is and dysfunction the demonstrated ischemia, conditions that designed death critical of to angiogenesis the ischemia, the animal of development coronary is through diseases CDXX+ flow to CDXX+ human condition cells studies cell Previously supply product thereby have development administration has address these of candidates to that of not and restricted. caused including limb area which induces cell CDXX+ blood the tissue our tissue caused therapeutic prompt microvascular healthy be Our in to a and the to several published of cells believe We ischemic the application can insult. new blood contributing but of underlying refractory the capillaries, conditions angina. ischemic of
an others, of limb specifics to ischemia has Japan. cell I'll to of nearest our CDXX+ in beginning spawned CDXX+ CLBSXX, Japan. programs study technology treatment for in with registration the eligible clinical is which our product product development the Now critical CLBSXX speak technology-based clinical our commercialization Among the in of our ongoing candidate currently
the a to but amputation. CLI of with disease. arteries rest treated it higher by most the documented, obstruction pain, skin the limited extremities note, feet legs is reduces often not if severe mobility, principally well significantly is eventual Please of well-known CLI patients CLI that experience non-healing that and arterial characterized represents blood and lower severe than a peripheral patients successfully ulcers, end-stage flow cancers. have that not and patients rate mortality the
six Labor in from designation to Welfare the filed. CLBSXX dedicated the the was regulatory application review States months and awarded akin well the designation CLI. a SAKIGAKE system review and development the a for SAKIGAKE once the registration of a RMAT to treatment affords consultation regulatory Japan and designation Ministry for support recipient of an is time as The as process prioritized United CLBSXX of designation reduced Health
study on also CLI controlled ongoing our is patients randomized early CLBSXX approval of based prospective and for in full possibly eligible complete multicenter open-label nature conditional the approval Japan. compelling the in data from
for acute classification to cellular medical therapeutic In or intended or achievement genetic or or to level. human addition, CLBSXX European sets us regulatory with ATMP diseases solutions treatment define the plan treatments path registration permanent the Medicines defined European CLI. expeditious and work chronic based CLBSXX or for most advanced This granted at Agency ATMP are tissue the to in regulators are on medicinal genes the regulatory for to as therapy of that closely EU. and are stage long-term a product cells as
traditional often Those a were to in in through and single intramuscular a sclerotic with disease care with with treatment of in XX-subject series The group of smoking. Japan standard with treatment associated pharmacotherapy. group ongoing into divided of subjects CLBSXX subjects injections two Buerger's comprises randomized type a a CLI dosed subjects addition are receiving CLI cohorts heavy arterial study seven to
the the progressing. anticoagulants to control by their approved is drugs standard arm in randomized only vasodilators and study which rescue deemed to subjects the The for of be is Subjects arm allows agent, of to protocol. care CLI with the if treatment antiplatelet to crossover according control indicating received Japan investigators choice including made by the the in
reverting prevent visits improved which pain in to the limb. defined and non-healing determined to is condition show The are skin Dictates consequences objective primary CLI-free this two of independent afflicted in, healed by that the absent blood can serious of monthly consecutive previous by is CLI a adjudication as committee. ulcers as through CLBSXX completely the flow an is rest study patients
the can the published consistent as effect in safety observed reported trials review company corporate our as States. clinical therapeutic the our to Buerger's presentation with profile Japan previously responses very in you and and are beneficial disease and positive reported, the in in As United website, and date on cohort previously
available with disease, Buerger's amputation amputation. no are pharmacotherapies and outcomes death patients and even For likely prevent
remarkable remission repeating disease Buerger's the endpoint to is rate cohort seven our natural XX% likely four meaning in It in CLI-free. a our its of patients disease progression study in subjects of met of that continued However, the have leading amputation. history achieved enrolled Buerger's disease subjects have fully the primary now that worth
extraordinarily So are our data positive.
We by that the outcome suggest data all overall conclusions that date positive on all trial will final they dependent the be the of the and however, from subjects. to recognizing, are study believe very trial a for encouraged results
anticipate data in or will recent early an have to the with a complete the early negative year remaining first this in COVID-XX XXXX. to top XXXX, to needed in leading That too during for possible is complete approval on said, Japan continue of late to study in Japan early trial. if line the XXXX in half We full study rate earliest the subjects the tell of enrollment coronavirus enrollment the impact outbreak for it
transfer Regarding study end, with remains conversations a and deal continue our Japan. that or partner consummate And commercialization, to before. in our see of prospective with in we if to the continue to the license not completion strategy CLBSXX partners to
dysfunction, a recently CLBSXX, CMD infusion the case product heart blood injection evaluating the is trial, our of Like candidates, vessel patented product an is with for the CLBSXX an ischemic of into formulation to microvascular now near the at/or the cells, treatment the heart our of CDXX XX-patient proprietary and a uses a which in no all therapy treatment in the microvascular promising CLBSXX insult, arterial completed cell and plaqueless a specifically subject candidate of for CDXX-positive CLBSXX of dysfunction. for discernible coronary site to trial designed a coronary tiny CDXX-positive Turning interlining clinical ESCaPE-CMD proof-of-concept large the blockages. disease coronary as damage involving artery. vessels of
large the prognosis aren't poor seen because disease, But equally obvious have an patients cardiac large vessel as CMD is vessel untreated. major to large Despite and CMD or often misdiagnosed absence patients to under blockages blockages. death have of who adverse events identifiable diagnosed, related artery
increase issue. me, CMD It innate physiology designed CMD is health the the in – address and to of this to frequently care women's excuse cells is should important by also CDXX-positive encountered an emerging ability employing an noted that be females more symptoms microcirculation. emerging making CLBSXX
showed supportive November only CLBSXX. something patients significant the their of XXXX, in ESCaPE-CMD that reserve visit quantitative improvement defining a cells with the development CLBSXX, but for action the evidence next with which coronary CDXX for corroborating Association in the the CMD not trial important is are they relief patients all flow for who our provide of American correlating trial. step our sessions data is of in the In administration after the humans, scientific single at And of of month direct of ESCaPE-CMD of first for programs. reported highly those time completed results XX XX six follow-up data the we at symptom statistically The had Heart mechanism
timing results complete noteworthy set scientific of initial The we outstanding the presentation scientific to a in acceptance at is of look journal, complete the publication reporting first dependent or results the were upon conference. or half in XXXX the data and which for forward of
IIb planning development CLBSXX study for next are the expeditiously possible in target advance with program to its as a to first Phase clinical sometime We a step around patient midyear. as
all angina being United on CLBSXX is an the or to developed patients vessel of angina, microvasculature treated have disease candidate refractory NORDA debilitating moving therapy with heart now to large III-ready due deficiency. And address CDXX no-option our likely Phase still those by had microvasculature growth have cell therapies disabling oxygen-deprived to but in product States new CLBSXX. the in stimulating available and who
confidence therapeutic the effect based with long-term of series improve condition. Phase Our increase is program of and and a in cells associated tolerance a X published consistency heart to function on that mortality exercise results study X, of this X decrease indicate CDXX-positive
both Among capital vigorously. possible which would we As discussed deferred confirmatory the confidence U.S. the of sources have pending initiation its the on quarterly non-dilutive and/or with are to in a are partnerships registration to in Phase we cost the completion. CLBSXX fund require study, last design FDA finalized sufficient that NORDA X projected pursuing capital of we study call, the of U.S. the our trial of to the to the for grants protocol support But due for
are XXXX the So expect development we a XXXX. from corporate throughout these number and that key and we made the which very in foundation with milestones accomplishments believe throughout pleased to of achievements closing, form attain
and to patients committed our of advancement Our as to innovative need and health. experienced, efficient options and programs passionate effective work in team to bring restore treatment dedicated the we human remains
operator overview, that take to with And we're now ready questions.
